'Off-the-shelf'allogeneic CAR T cells: development and challenges

S Depil, P Duchateau, SA Grupp, G Mufti… - Nature reviews Drug …, 2020 - nature.com
Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …

Allogeneic CAR cell therapy—more than a pipe dream

KJ Caldwell, S Gottschalk, AC Talleur - Frontiers in immunology, 2021 - frontiersin.org
Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors
(CARs) has shown promise, particularly for the treatment of hematological malignancies. To …

CD1: antigen presentation and T cell function

M Brigl, MB Brenner - Annu. Rev. Immunol., 2004 - annualreviews.org
▪ Abstract This review summarizes the major features of CD1 genes and proteins, the
patterns of intracellular trafficking of CD1 molecules, and how they sample different …

[HTML][HTML] Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining

JE Gumperz, S Miyake, T Yamamura… - The Journal of …, 2002 - ncbi.nlm.nih.gov
CD1d-restricted natural killer (NK) T cells are known to potently secrete T helper (Th) 1 and
Th2 cytokines and to mediate cytolysis, but it is unclear how these contrasting functional …

Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals

PJ Brennan, RVV Tatituri, M Brigl, EY Kim, A Tuli… - Nature …, 2011 - nature.com
Invariant natural killer T cells (i NKT cells) have a prominent role during infection and other
inflammatory processes, and these cells can be activated through their T cell antigen …

[HTML][HTML] Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting

A Rotolo, VS Caputo, M Holubova, N Baxan, O Dubois… - Cancer Cell, 2018 - cell.com
Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical
remissions in CD19+ B cell lymphomas are often short lived. We tested whether CAR19 …

Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial

MA Exley, P Friedlander, N Alatrakchi, L Vriend… - Clinical Cancer …, 2017 - AACR
Abstract Purpose: Invariant NKT cells (iNKT) are innate-like CD1d-restricted T cells with
immunoregulatory activity in diseases including cancer. iNKT from advanced cancer patients …

Loss of IFN-γ production by invariant NK T cells in advanced cancer

S Muhammad Ali Tahir, O Cheng… - The Journal of …, 2001 - journals.aai.org
Invariant NK T cells express certain NK cell receptors and an invariant TCRα chain specific
for the MHC class I-like CD1d protein. These invariant NK T cells can regulate diverse …

[HTML][HTML] Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype

A Pallier, S Hillion, R Danger, M Giral, M Racapé… - Kidney international, 2010 - Elsevier
Several transplant patients maintain stable kidney graft function in the absence of
immunosuppression. Here we compared the characteristics of their peripheral B cells to that …

A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell …

S Motohashi, K Nagato, N Kunii… - The Journal of …, 2009 - journals.aai.org
To evaluate the safety, immune responses, and antitumor responses after the administration
of α-galactosylceramide (αGalCer) KRN7000-pulsed PBMC cultured with IL-2 and GM-CSF …